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Abstract  27 
Purpose: To identify the period prevalence of hormonal contraceptive (HC) use and 28 
characterise the perceived side effects associated with the menstrual cycle and HC use. 29 
Methods: 430 elite female athletes completed a questionnaire to assess; the period prevalence 30 
of HC use, the reasons for initiation and discontinuation of HCs and the side effects experienced 31 
by HC and non-HC users. Descriptive statistics, between-group comparisons and associations 32 
between categorical variables were calculated. Results: 49.5% of athletes were currently using 33 
HCs and 69.8% had used HCs at some point. Combined oral contraceptives were most 34 
commonly used (68.1%), with 30.0% using progestin-only contraceptives (implant = 13.1%; 35 
injection = 3.7%; intrauterine system = 2.8%). Perceived negative side effects were more 36 
common with progestin-only HC use (39.1%) compared to combined HC use (17.8%; P = 37 
0.001) and were most prevalent in implant users (53.6%; P = 0.004). HC users reported 38 
perceived positive side effects relating to the ability to predict and/or manipulate the timing, 39 
frequency and amount of menstrual bleeding. Non-HC users had a menstrual cycle length of 40 
29 ± 5 d and 77.4% reported negative side effects during their menstrual cycle, primarily during 41 
days 1-2 of menstruation (81.6%). Conclusions: Approximately half of elite athletes used HCs 42 
and progestin-only contraceptive users reported greater incidences of negative side effects, 43 
especially with the implant. Due to the high inter-individual variability in reported side effects, 44 
athletes and practitioners should maintain an open dialogue to pursue the best interests of the 45 
athlete. 46 
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Introduction 52 
Alterations to the female reproductive-axis influence health and athletic performance.1–3 53 
Between menarche and the menopause, non-hormonal contraceptive users typically have a 54 
monthly menstrual cycle, with a cyclical rise and fall in sex hormone concentrations.4 Primary 55 
dysmenorrhea, which is characterised by painful menstruation, nausea, headaches, fatigue and 56 
diarrhoea,5 is experienced by 60-91% of non-hormonal contraceptive users6 and may affect 57 
athletic performance.7 In a recent study, 51% of athletes (n = 90) perceived that the menstrual 58 
cycle affected their training and performance.8 Despite this, little is known about menstrual 59 
cycle related side effects, when they occur and how training and performance may be 60 
influenced. 61 
 62 
Hormonal contraceptives (HCs) are exogenous steroid hormones that inhibit ovulation and 63 
result in consistently low endogenous sex hormone concentrations, which can be used to treat 64 
dysmenorrhea.9,10 There are different delivery methods for HCs including the oral 65 
contraceptive (OC), implant, injection, transdermal patch, vaginal ring and intra-uterine system 66 
(IUS). In the UK, a hormone releasing coil is typically referred to as an IUS, whereas a copper-67 
based, non-hormone releasing coil is referred to as an intra-uterine device (IUD) and, as such, 68 
would not be considered a type of HC. Hormonal contraceptives can also be classified by type; 69 
combined, with an oestrogenic and progestin component, or progestin-only. The type and 70 
concentration of oestrogen and progestin varies between different preparations of contraceptive, 71 
and may influence the physiological response.11–13 72 
 73 
In a large-scale epidemiological study of >194,000 women, Cea-Soirano et al.14 reported that 74 
30% of 16-49 year olds in the UK used HCs: combined OCs (16.2%), progestin-only OCs 75 
(5.6%), IUSs (4.2%), injections (2.4%), implants (1.5%), transdermal contraceptive patches 76 
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(0.1%), with 4.5% using non-hormonal copper-based coils (IUDs). The prevalence of HC use 77 
in athletes has been poorly defined by previous research. In elite Norwegian athletes, OC use 78 
was 40.2%, which was significantly higher than a control population (27%),15 while 46% of 79 
Swedish football, volleyball and basketball athletes used OCs.16 Other studies have reported 80 
low OC use in athletes (~14%),17,18 although this may be due to the inclusion of non-elite 81 
athletes, who may be more analogous to the general population. Previous research in elite 82 
athletes has only reported OC use and has not considered other delivery methods of HCs or 83 
detailed the preparations used by participants, which influence endogenous hormone 84 
concentrations and other physiological processes.11–13 No study has identified the reasons why 85 
elite athletes initiate or discontinue HC use, or the perceived side effects. 86 
 87 
Elite female athletes are required to train and compete whilst having to manage changes in sex 88 
hormone concentration and their subsequent side effects. The current lack of understanding of 89 
these side effects is a barrier to implementing strategies to support athletes and promote optimal 90 
health and performance. The aim of this study was to identify (1) the period prevalence of HC 91 
use, (2) the reasons for initiation and discontinuation of HCs and (3) the side effects 92 
experienced by HC users and non-users in an elite athletic population. 93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
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Materials and methods 104 
Participants 105 
Between 2015-2016, elite female athletes were recruited through National Governing Bodies, 106 
coaching and support staff, or by approaching the athletes directly. Athletes had to be >18 y 107 
and competing at a national, international or professional (full-time and salaried) level. A 108 
paper-based questionnaire was used in order to minimise the possibility that the questionnaire 109 
could be completed by the non-targeted population.19 A total of 476 athletes completed the 110 
questionnaire, with 430 responses included in the final analysis (Figure 1). Athletes were 111 
recruited from 24 sports with 361 competing at an international/professional level and 69 112 
competing nationally. All participants provided written informed consent and the study was 113 
approved by the Nottingham Trent University non-invasive ethics committee.  114 
 115 
Questionnaire 116 
Data were collected using a paper-based questionnaire that was specifically designed for the 117 
purposes of the study. All data were provided by the athletes and reflect their perceptions and 118 
experiences. Participants recorded demographic information including age, height, weight, age 119 
of menarche, sport, competitive level, length of time competing at this level and weekly 120 
training frequency and duration (Table 1 and Figure 1). Current HC users and non-HC users 121 
were directed to complete different sections of the questionnaire. Non-HC users were asked 122 
whether they used a IUD, their typical menstrual cycle duration and variability in length. 123 
Participants were asked to state whether they experienced pain or other symptoms during the 124 
menstrual cycle and whether they avoided exercise/training at any point of their cycle. Where 125 
applicable, participants were asked, in an open-ended question, to state the symptoms/reasons 126 
and time points when these occurred. Current HC-users were asked to provide the delivery 127 
method, preparation and duration of use for their current HC. Participants were asked whether 128 
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they had discussed their HC with their coach/team doctor and whether the coach/team doctor 129 
was involved in the decision to use this type of HC. Participants were asked why they had 130 
chosen this method of HC, whether they considered possible side effects prior to commencing 131 
HC use, and whether they have experienced any negative or positive side effects. Where 132 
applicable, participants were asked to provide supporting information in an open-ended 133 
question. Non-HC users and HC users were then asked to detail previous HC use, including 134 
the delivery method, preparation, duration of use and reason for discontinuation for all previous 135 
HCs used.  136 
 137 
Data analysis 138 
Data were analysed using Microsoft Excel and IBM SPSS (v. 23.0). To prevent duplicate data, 139 
the database was searched for non-unique date of births and identical values were visually 140 
checked to assess whether the respondents were different. Athletes were categorised by 141 
competitive level (national or international/professional) to conduct a stratified analysis. For 142 
open-ended questions, a content analysis was conducted independently by two researchers 143 
(DM, KES) to categorise responses, whereby a frequency analysis was performed, which was 144 
checked for consistency. Differences between the researchers were resolved by discussion until 145 
a consensus was reached. Direct verbatim quotes were used to inform interpretation in some 146 
instances. Assumptions of normality were checked using the Shapiro-Wilk test and between 147 
group differences were examined using independent samples t-tests, Mann-Whitney U tests 148 
and Kruskal Wallis H tests. Pearson’s chi-squared analyses were used to examine the 149 
relationships between categorical variables, with Fishers exact tests used where <80% of 150 
expected cell counts were >5.20 Data are represented as mean ± 1SD, frequencies and 151 
percentages and statistical significance was set at p ≤ 0.05.  152 
 153 
 154 
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Results 155 
Three hundred (69.8%) athletes reported using HCs at some point, with 49.5% of athletes 156 
currently using HCs and 50.5% not currently using any form of HC (Fig 1). Hormonal 157 
contraceptive users had a lower age of menarche (p = 0.010) and length of time competing at 158 
current level (p = 0.048) compared to non-HC users (participant characteristics in Table 1). 159 
Competitive level did not influence the prevalence of HC use (p > 0.05). 160 
 161 
Menstrual cycle (non -hormonal contraceptive users) 162 
Three athletes described themselves as amenorrheic, although the questionnaire did not 163 
specifically ask this question. Thirty-four athletes did not report their menstrual cycle length or 164 
did not provide enough information to interpret a response. Mean cycle length for the remaining 165 
athletes was 29 ± 5 d. Eight athletes reported a mean menstrual cycle duration of greater than 166 
35 days and three athletes reported a mean menstrual cycle duration of less than 21 days. One-167 
hundred and four (48.6%) athletes stated that their menstrual cycle was non-variable in length, 168 
while 110 (51.4%) athletes reported their cycle length to be variable with a mean variation of 169 
9 ± 9 d. Copper IUDs were used by 2 participants (0.9%); with a mean menstrual cycle length 170 
of 28 ± 4 d. Menstrual cycle-related negative symptoms were reported by 168 athletes (77.4%) 171 
and categorical frequencies are presented in Table 2. Symptoms were experienced in the week 172 
prior to menstruation (25.0%), during days 1 and 2 of menstruation (81.6%) and between day 173 
3 and the end of menstruation (28.9%). Nine athletes (4.1%) reported that they had to refrain 174 
from exercise at certain points of their menstrual cycle. Reasons included pain (n = 4), sickness 175 
(n = 2), or other reasons (n = 3), such as “Literally struggle to get out of bed so training is out 176 
of the question” or “at the beginning of the menstrual cycle I avoid to do tough session [sic]”. 177 
Four athletes reported that they didn’t refrain from exercise, although they provided additional 178 
comments stating “No – but only because I can’t”, “but struggle with contact [rugby]”, “but I 179 
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get back cramps 1 week before when running” and “I don’t avoid it but I do sometimes have 180 
to delay things until cramps calm down”. One athlete stated that “If anything I have to increase 181 
it [exercise]. Helps to pass quicker by maybe a day and helps the pain”. 182 
 183 
Hormonal contraceptive use 184 
Combined HCs comprised 68.5% of HC use, with 30.0% using progestin-only and 1.9% using 185 
an unspecified type of OC. There was no difference in length of current HC use between 186 
combined (4.6 ± 3.7 y) and progestin-only HC users (3.9 ± 4.4 y; p = 0.193), or between 187 
different delivery methods (p = 0.649). Oral contraceptives were the most widely used (78.4%), 188 
followed by the implant (13.1%), injection (3.8%), IUS (2.8%) and vaginal ring (0.5%), with 189 
one participant using a combination of the implant and OC. All combined OCs were 190 
monophasic and contained ethinyl oestradiol (EO) as the oestrogenic component in varying 191 
doses: 20 µg (n = 4, 2.8%), 30 µg (n = 116, 80.0%), 35 µg (n = 19, 13.1%). Six participants (n 192 
= 4.1%) used combined preparations but did not specify the oestrogenic dose. Twelve different 193 
progestins were used in various doses, with Levonorgestrel accounting for 51.4% of progestin 194 
use.  195 
 196 
The most common reason athletes chose their specific type/delivery method was ease of use 197 
(18.8%), and the most common side effects considered prior to HC use were weight gain (33%) 198 
and mood changes/swings (12.7%). The side effects experienced by HC-users are shown in 199 
Table 3. Negative side effects were significantly more common with progestin-only HCs 200 
(39.1%) compared to combined HCs (17.8%; p = 0.001) and were significantly more common 201 
in the implant (53.6%) compared to other delivery methods (p = 0.004; Table 4). Type and 202 
delivery method of HC did not affect the prevalence of reported positive effects (p > 0.05). HC 203 
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users were significantly more likely to report positive effects of HCs than negative effects (p < 204 
0.05).  205 
 206 
International/professional athletes were significantly more likely to discuss HC use with their 207 
coach/team doctor (25%) compared to national level athletes (0%; p < 0.001). Competitive 208 
level did not influence coach/team doctor involvement in the decision to initiate HC use (p = 209 
0.070), although this did occur for 7.6% of international/professional athletes and no national 210 
level athletes. The coach/team doctor was involved in the decision to use HCs for 14 (6.6%) 211 
athletes, of which 12 used OCs and 2 used an implant. Ultra-low dose EO (20 µg) OCs 212 
accounted for 25% of OC use in this group, in comparison to 2.7% of overall OC use, which 213 
was a significant effect (p = 0.010). Where the coach/team doctor was involved in the decision, 214 
athletes stated that they were prescribed these HCs for contrasting reasons including; ‘Higher 215 
level of oestrogen”, “Apparently lowest oestrogen”, “Low hormones” and “In attempt to reduce 216 
monthly fluctuations in my performance and fatigue”. 217 
 218 
In total, 87 (40.1%) non-HC users had previously used some form of HC, with 64 (30.0%) 219 
current HC users previously using a different HC. There were 218 incidences of previous HC 220 
use, as some athletes had used 2 (n = 49), 3 (n = 13), 4 (n = 4) and 5 (n = 1) previous types of 221 
HC. Combined OCs accounted for 78.4% of previous use, with progestin-only OCs (7.8%), 222 
implant (7.8%), injection (6.0%) and IUS (1.8%) also used. The reasons provided for 223 
discontinuation of previous HCs are presented in Table 5. Mean duration of previous HC use 224 
was 2.2 ± 2.3 y, with no difference between types (p = 0.360) or delivery methods (p = 0.733). 225 
 226 
 227 
 228 
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Discussion 229 
This novel study has shown that there is an approximately even prevalence of HC use and non-230 
HC use in elite female athletes. The majority of female athletes have used HCs at some point 231 
in their sporting career. These results highlight the importance of understanding the effects of 232 
the menstrual cycle and HC use in elite sportswomen. This is the first study to detail the 233 
symptoms experienced by athletes during the menstrual cycle and with HC use, and these data 234 
can be used to inform the decisions of athletes, practitioners and researchers. 235 
 236 
The prevalence of HC use in elite athletes (49.5%) is higher than recent data for the general 237 
population of reproductive age in the UK (30.0%)14 and USA (27.6%).21 Sixty-nine percent of 238 
HCs used were combined OCs, which is also higher than in the general population where OCs 239 
account for 54.0% of HC use.14 Schaumberg et al.22 , showed that competitive (state, national 240 
and international) athletes rated sport competition and sport training as more important factors 241 
in menstrual manipulation with OCs, compared to sub-elite and recreationally active 242 
individuals. Furthermore, 43.5% of OC-using competitive athletes planned to manipulate 243 
menstruation often, which was greater than sub-elite (22.5%) and recreationally active women 244 
(15.8%). In the current study, nearly a third of combined OC users perceived the ability to 245 
predict or manipulate menstruation, thereby avoiding menstruation during training or 246 
competition, as a positive effect, which may explain the differences in OC use between elite 247 
athletes and the general population. Progestin-only HCs accounted for 30.0% of use, with the 248 
implant (13.1%) and progestin-only OC (10.3%) being the most widely used. Almost 40% of 249 
progestin-only HC users perceived the cessation of, or less frequent bleeding, as a positive 250 
consequence of this type of HC. Previous research has documented the prevalence of OC use 251 
in athletes.15,16 however the current study has provided a more comprehensive overview of HC 252 
use by including all types and delivery methods of HCs, in addition to the preparations, which 253 
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enables the quantification of steroid hormone content and concentrations. Twelve different 254 
progestins were used in varying concentrations, with EO being the oestrogenic component in 255 
all combined preparations. Four HC users were prescribed ultra-low dose (20 µg EO) OCs; 256 
with three cases involving the coach/team doctor in the decision to use this preparation, all of 257 
which were from different sports. Ultra-low dose OCs are associated with reduced headaches, 258 
nausea and breast tenderness compared to higher dose EO formulations23 and can reduce the 259 
symptoms of dysmenorrhea24, so may have been prescribed to reduce these symptoms whilst 260 
maintaining the benefits of improved cycle control. These data are representative of a UK based 261 
population and further studies are required to expand this knowledge to other countries where 262 
the use of other formulations, such as extended cycle OCs, are more prevalent.25 263 
 264 
Combined HCs were better tolerated than progestin-only HCs; with 17.8% of combined-type 265 
users reporting negative side effects in comparison to 39.1% of progestin-only HC users. In 266 
particular, the implant had a significantly higher incidence of reported negative symptoms 267 
compared to other delivery methods of HCs (Table 4). One third of athletes considered weight 268 
gain as potential side effect prior to HC initiation, although only 7.5% reported increased 269 
weight which is lower than in the general population (34%).26 Hormonal contraceptive users 270 
were more likely to report positive than negative side effects, which may have implications for 271 
athletes considering HC use in the future. Nineteen negative and 23 positive categories of side 272 
effects were identified, emphasising the individuality of responses and that athletes should be 273 
considered on a case by case basis. The most prevalent, positive side effects reported were the 274 
ability to predict/change menstruation (n = 45), having regular periods (n = 27) and cessation 275 
of/less frequent bleeding (n = 26), showing that changes to the timing, frequency and amount 276 
of bleeding with HC use were well-received. It should be noted that athletes were asked to state 277 
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the non-contraceptive benefits of HC use, therefore the primary benefit and reason of HC use 278 
may have been for contraception. 279 
 280 
Sixty-four (30.0%) HC users previously used a different form of HC and 87 (40.1%) non-HC 281 
users had previously used a form of HC. The most common reasons provided for 282 
discontinuation of HCs were: they were no longer needed (19.9%), they altered mood (19.2%), 283 
resulted in weight gain (18.5%) and caused headaches/migraines (11.9%). It is important to 284 
note that 46 separate reasons were provided for discontinuation of HCs, emphasising the high 285 
inter-individual response. This further emphasises that sport practitioners should openly 286 
discuss HC use and side effects with athletes to monitor athletes’ health, well-being and 287 
performance.   288 
 289 
Negative side effects associated with the menstrual cycle were reported by 77.4% of non-HC 290 
users, which is similar to the general population.6 Exercise may reduce the occurrence and 291 
severity of dysmenorrhea,27 although dysmenorrhea is still widespread in elite athletes. The 292 
most commonly reported side effects were stomach cramps (47.5%), unspecified cramps 293 
(22.1%), back pain (17.1%) and headaches/migraines (9.7%). Despite having physically 294 
demanding lifestyles, only 4.2% of athletes stated that they refrained from exercise at certain 295 
points of their menstrual cycle, which is lower than the general population where dysmenorrhea 296 
limits daily activities in 15-29% of women.6 This discrepancy may be caused by internal and 297 
external pressures to perform,28 meaning that athletes persevere with training whilst 298 
experiencing severe symptoms, evidenced by responses such as “No, but only because I can’t 299 
[avoid exercise]”. A recent study in HC users and non-users, showed 51.1% of athletes thought 300 
their menstrual cycle affected training and performance,8 although the current data indicates 301 
that this rarely translates into athletes modifying training schedules to accommodate symptoms.  302 
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 303 
Twenty-four distinct, negative symptoms were reported by non-HC users (Table 2) and 304 
approximately half of the athletes reported menstrual cycle length variability with a relatively 305 
high mean variation of (9 ± 9 d) in these athletes. Although the current questionnaire did not 306 
ask specifically about amenorrhea, three athletes described themselves as amenorrheic, and we 307 
recommend that future studies explicitly ask this question in order to not under-represent the 308 
occurrence of amenorrhea in elite sport. Side effects were mostly experienced during the first 309 
two days of menstruation (81.6%), however also occurred in the week prior to menstruation 310 
(25.0%) and between day 3 and the end of menstruation (28.9%). These data emphasise the 311 
individuality of responses and the importance of athletes monitoring their menstrual cycle and 312 
associated symptoms. We suggest that athletes and coaches/support staff should maintain an 313 
open dialogue about the menstrual cycle and encourage flexibility in training schedules, when 314 
possible, to accommodate the most severe side effects. 315 
 316 
With half of elite athletes using HCs, future research should include HC users and non-users 317 
in order to represent the female athlete population.  Progestin-only contraceptives constitute 318 
~30% of HC use in athletes, although we are unaware of any research available to identify the 319 
effects of these contraceptives on athletic performance and health. Twenty-five different 320 
preparations of HC were identified in this study, containing different doses of oestrogens and 321 
progestins, which may have different physiological effects.11–13 Therefore, future research 322 
should focus on (1) examining differences in responses between HC users and non-users, (2) 323 
progestin-only contraceptive users and (3) differences between preparations of HC.  324 
 325 
Practical Applications  326 
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Progestin-only contraceptives had a greater incidence of negative side effects and physicians 327 
may want to consider the increased prevalence of perceived negative side effects with these 328 
contraceptives. There is a large degree of individuality in the type and severity of symptoms 329 
experienced during the menstrual cycle and HC use, and in the reasons for initiating and 330 
discontinuing HC use. It is recommended that athletes and practitioners discuss side effects 331 
experienced with the menstrual cycle and HC use in order to suit the athletes’ best interests. 332 
This research also highlights that future research should include HC users and non-users in 333 
order to represent the female athlete population. 334 
 335 
Conclusions 336 
Approximately half of elite athletes use some type of HC, with combined OCs most commonly 337 
used, possibly due to the ability to predict and/or manipulate the timing, frequency and amount 338 
of menstrual bleeding. A large proportion of sportswomen use progestin-only contraceptives 339 
with a perceived benefit being that they induce amenorrhea. There is a larger inter-individual 340 
variability in response to HC use and the menstrual cycle which should be considered by 341 
athletes and practitioners. 342 
 343 
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 440 
Fig 1. The prevalence of type, delivery method and preparation of hormonal contraceptives (HCs) used and the prevalence of non-HC use. IUD, 441 
Intrauterine device; IUS, Intrauterine system; DNS, dose not specified; OC, oral contraceptive.442 
Total number of questionnaire 
responses (n = 476) 
Responses included in analysis 
(n = 430) 
Excluded 
No consent (n = 2) 
<18 y (n = 3) 
Duplicate completion (n = 5) 
Insufficient completion (n = 6) 
Non-elite athlete (n = 26) 
Non-UK based (n = 4) 
Currently non-HC 
users (n = 217) 
Current HC users 
(n = 213) 
Copper IUD 
(n = 2) 
Never used HCs 
 (n = 130) 
Previously used 
 HCs (n = 87) 
Progestin only 
 HCs (n = 64) 
Unspecified OC 
brand (n = 4) 
Combined HCs 
(n = 146) 
OC 
 (n = 22)  
Cerazette® (n=10) 
Cerelle® (n=8) 
Noriday® (n=3) 
Nacrez® (n=1) 
 
Implant 
 (n = 28)  
Nexplanon® (n=11) 
Norplant® (n=10) 
Not specified (n=5) 
Implanon® (n=2) 
  
Injection 
 (n = 8)  
Depo Provera® (n=8)  
  
IUS 
 (n = 6)  
Mirena® (n=6)  
  
Vaginal ring 
 (n = 1)  
NuvaRing® (n=1)  
  
Hockey 
Football 
Rugby 
Athletics   
Rowing  
Cricket  
Netball 
Squash 
n = 103 
n = 83 
n = 55 
n = 32 
n = 25 
n = 22 
n = 21 
n = 12 
Judo 
Kayak 
Basketball 
Boxing 
Badminton 
Canoe 
Diving 
Archery 
n = 11 
n = 8 
n = 8 
n = 7 
n = 7 
n = 6 
n = 6 
n = 6 
Triathlon 
Short track 
Table tennis 
Taekwondo 
Trampoline 
Swimming 
Cycling  
Orienteering 
 
n = 4 
n = 4 
n = 3 
n = 3 
n = 1 
n = 1 
n = 1 
n = 1 
OC 
 (n = 145)  
Microgynon® (n=52)  
Rigevidon® (n=27) 
Cilest® (n=16) 
Yasmin® (n=9) 
Levest® (n=8) 
Marvelon® (n=8) 
Ovranette® (n=6) 
Loestrin® 20 (n=4) 
Gedarel® DNS (n=3) 
  
OC 
(n = 145)  
Femodene® (n=2) 
Dianette® (n=2) 
Milinette® DNS (n=2) 
Anastrella® (n=1) 
Gedarel® 20 (n=1) 
Gedarel® 30 (n=1) 
Ogestrel® (n=1) 
Loestrin® DNS (n=1) 
Demulen® (n=1) 
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Table 1. Participant characteristics for hormonal contraceptive (HC) users and non-HC users. 443 
Demographic information HC users Non HC users Total 
Age (y) 24.1 ± 4.5 24.3 ± 4.3 24.2 ± 4.4 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 66.2 ± 9.8 66.0 ± 9.3 66.1 ± 9.6 
Body mass index (kg·m2) 23.1 ± 2.6 23.0 ± 2.5 23.1 ± 2.5 
Age at menarche (y) 13.4 ± 1.5 13.8 ± 1.3 13.6 ± 1.4* 
Gynaecological age (y) 10.7 ± 4.6 10.6 ± 4.6 10.6 ± 4.6 
Duration competing at current level (y) 5.0 ± 3.6 5.7 ± 4.1 5.4 ±3.9* 
No. training session per week 8.5 ± 4.5 8.4 ± 4.0 8.5 ± 4.3 
Average training session duration (mins) 92.8 ± 29.8 89.1 ± 27.8 90.9 ± 28.8 
Total weekly training duration (mins) 769.7 ± 440.8 720.3 ± 385.6 744.6 ± 413.9 
* Indicates a significant difference between HC users and non-HC users (p < 0.05) 
 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
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 454 
 455 
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Table 2. Frequency and prevalence of physical and emotional symptoms reported during the 458 
menstrual cycle for non-hormonal contraceptive users. 459 
 
Symptom Frequency Prevalence (%) 
Physical  Stomach cramps/abdominal pain 103 47.5 
 
Unspecified cramp 48 22.1 
 
Back pain  37 17.1 
 
Headache/migraine 21 9.7 
 
Bloating 12 5.5 
 
Nausea/sickness/vomiting 10 4.6 
 
Tiredness/fatigue/lethargy 9 4.1 
 
Dizzy/lightheaded/lack of coordination 5 2.3 
 
Leg discomfort 4 1.8 
 
Unspecified pain 3 1.4 
 
Hot flushes/sweating 2 0.9 
 
Hunger/increased appetite 2 0.9 
 
Sore breasts 2 0.9 
 
Bad skin 1 0.5 
 
Constipation 1 0.5 
 
Heavy bleeding 1 0.5 
 
Muscle ache 1 0.5 
 
Problems with exercise 1 0.5 
 
Sore throat 1 0.5 
 
Tight neck 1 0.5 
 
Weakness 1 0.5 
Emotional  Mood changes/swings 9 4.1 
 
Irritability 1 0.5 
 
Flustered 1 0.5 
 460 
 461 
 462 
 463 
 464 
21 
 
Table 3. Prevalence of reported negative and positive side effects for current hormonal contraceptive use. 465 
 
Negative effect Frequency Prevalence (%) Positive effect Frequency Prevalence (%) 
Physical Weight gain 16 7.5 Regular period 27 12.7 
 
Irregular periods 9 4.2 Cessation of/less frequent periods 26 12.2 
 
Poor skin 6 2.8 Reduced bleeding/lighter periods 23 10.8 
 
Headaches/migraines 4 1.9 Improved skin 13 6.1 
 
Altered cycle length 3 1.4 Reduced period pain 10 4.7 
 
Breast issues (bigger/sore) 3 1.4 Reduced cramps (unspecified) 7 3.3 
 
Constant/irregular bleeding 3 1.4 Reduced pain (unspecified) 6 2.8 
 
Spotting 3 1.4 Reduced headaches/migraine 3 1.4 
 
Tiredness/fatigue/lethargy 3 1.4 Increased iron 3 1.4 
 
Effect on training/performance 2 0.9 Less ill/sick 3 1.4 
 
Nausea/sickness/vomiting 2 0.9 Resumption of cycle from amenorrhea 3 1.4 
 
Water retention 2 0.9 Reduced stomach cramps 3 1.4 
 
Abnormal liver function 1 0.5 Effect on training/performance 2 0.9 
 
Bloating 1 0.5 Reduced bloating 1 0.5 
 
Hormone imbalance 1 0.5 Improved bone density 1 0.5 
 
Increased appetite 1 0.5 Less faint 1 0.5 
 
Stomach pain 1 0.5 Reduced fluctuations in water retention 1 0.5 
 
Unspecified pain 1 0.5 Reduced fluctuations in weight 1 0.5 
    
Reduced PCOS side effects 1 0.5 
Emotional Mood changes/swings 9 4.2 Improved mood 3 1.4 
Both        Helps PMT 1 0.5 
Practical       Ability to predict/change cycle date 45 21.1 
    
Couldn’t forget to take 3 1.4 
PCOS, Polycystic ovarian syndrome; PMT, Pre-menstrual tension. 
466 
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Table 4. Prevalence of reported negative and positive effects of hormonal contraceptive use in current users, separated by type and delivery 467 
method of hormonal contraceptive 468 
  Type of hormonal contraceptive   Delivery method of hormonal contraceptive 
 Combined 
Progestin
-only 
Total  OC Implant Injection IUS 
Vaginal 
ring 
Total 
Experienced negative symptoms 26 25 51   35 15 2 2 0 54 
Didn’t experience negative symptoms 120 39 159  136 13 6 4 1 214 
Percentage with symptoms (%) 17.8 39.1 24.4*  20.5 53.6 25.0 33.3 0.0 25.2* 
                      
Experienced positive effects 99 42 141  117 18 3 5 1 144 
Didn't experience positive effects 47 22 69  54 10 5 1 0 70 
Percentage with symptoms (%) 67.8 65.3 67.1  68.4 64.3 37.5 83.3 100.0 67.3 
* Indicates a significant effect of type or delivery method (P < 0.05). OC, oral contraceptive; IUS, intrauterine system. 
 469 
 470 
 471 
 472 
 473 
 474 
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Table 5. Reasons, frequency and prevalence for discontinuation of previous hormonal 475 
contraceptives.  476 
 
Reason Frequency Prevalence (%) 
Physical symptoms Weight gain 28 12.8 
 
Headaches/migraine 18 8.3 
 
More frequent or heavier bleeding 13 6.0 
 
Irregular/no bleeding 10 4.6 
 
Poor skin 7 3.2 
 
Constant bleeding 6 2.8 
 
Fatigue/tiredness/lethargy 6 2.8 
 
Bone health 5 2.3 
 
Impaired training/performance/recovery 5 2.3 
 
Nausea/vomiting 4 1.8 
 
Resumption/regulation of menses 4 1.8 
 
Stomach cramps 3 1.4 
 
Stroke and cancer risk 3 1.4 
 
Water retention 3 1.4 
 
Cramps 2 0.9 
 
Hormone imbalance 2 0.9 
 
Impaired sleep 2 0.9 
 
Low libido 2 0.9 
 
Painful periods 2 0.9 
 
Bloating 1 0.5 
 
Blood pressure 1 0.5 
 
Blood side effects [sic] 1 0.5 
 
Breast pain 1 0.5 
 
Dizziness and blurred vision 1 0.5 
 
For oestrogen reasons [sic] 1 0.5 
 
Hot flushes 1 0.5 
 
Illness 1 0.5 
 
Pain during intercourse 1 0.5 
 
PMS 1 0.5 
 
Removed to assess oestrogen level 1 0.5 
Emotional symptoms Mood 29 13.3 
 
Wanting to be “normal” / “natural” 5 2.3 
 
Depression 4 1.8 
 
Needed a rest/break 3 1.4 
Practical Not sexually active/not needed 30 13.8 
 
Forgetting to take pill 16 7.3 
 
Doctor/nurse recommendation 11 5.0 
 
Didn’t like it 10 4.6 
 
Pregnancy 6 2.8 
 
New preparation/type 4 1.8 
 
Ran out 4 1.8 
 
Went abroad/travelling 4 1.8 
 
Ineffective 3 1.4 
 
Wanted something different/permanent 2 0.9 
 
Word of mouth 2 0.9 
 
Loss of effect[sic] 1 0.5 
 477 
 478 
